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Abstract: 
Purpose: Both beta thalassemia and restless legs syndrome (RLS) patients share some 
common pathophysiological characteristics related to iron handling. In the present 
study, the aim was to explore the prevalence of RLS as well as to explore potential 
association between the syndrome and various quality of life-related parameters in a 
sample of beta thalassemia patients.  
Methods: One hundred fourteen (age 40 ± 11yr, 59M/55F) beta thalassemia patients 
participated in this cross-sectional descriptive study. Patients were screened for RLS 
based to the international RLS study group diagnostic criteria as well as a battery of 
validated questionnaires.  
Results: The prevalence of RLS in this sample of beta thalassemia patients was zero. 
The quality of life score was low (78± 18). Iron levels were within normal range (191 
± 66 mcg/dL) while ferritin levels were high as expected (1836 ± 225ng/dL).   
Conclusions: Our sample of patients comes from central Greece where the prevalence 
of RLS in the general population is 4% while in renal failure patients is 27%. To our 
surprise there was no presence of RLS among this sample of beta thalassemia 
patients. The adequate levels of iron and ferritin often seen in these patients could be 
the reason of the absence of RLS symptoms. 
Keywords: anemia; iron; ferritin; sleep disorders 
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Introduction 
Beta thalassemia is a group of hereditary blood disorders characterized by reduced or 
absent synthesis of the beta chains of hemoglobin and anemia and leading therefore to 
unaffected erythropoiesis [1].Individuals with thalassemia major usually present 
within the first two years of life with severe anemia, requiring regular red blood cell 
transfusions. Regular transfusion therapy leads, among other, to iron overload-related 
complications.On the other hand, compliance with iron therapy mainly influences 
frequency and severity of the iron overload-related complications [2]. 
On the other hand, restless legs syndrome (RLS) (called also as Willis-Ekbom disease 
WED) is a sensorimotor neurological disorder related to dopaminergic pathways 
while the neuronal iron handling have been implicated in the pathophysiology of the 
syndrome [3]. RLS is characterized by an uncontrolled need to move extremities 
accompanied by unpleasant sensations, which frequently leads to sleep disturbances 
[4,5]. Symptoms are particularly troublesome in the evening and at night, and sleep 
disturbance is common [4].  
RLS is categorized as either primary or secondary. Primary RLS is associated with 
family history with some genetic risk factors to have been identified recently [6]. RLS 
susceptibility is strongly related to iron levels, however, iron-related genes do not 
seem to affect serum iron parameters while the correlation between RLS and iron 
parameters in serum seems to be weaker than assumed [7]. 
RLS can be presented as secondary to or exacerbated by, a number of conditions 
associated with iron deficiency and anemia such as pregnancy and end-stage renal 
disease [8]. This is also the case in peripheral iron deficiency with or without anemia 
which appears to be an important environmental trigger of RLS symptoms [9]. 
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Studies carried out in populations with iron deficiency anemia report approximately 
35% with RLS symptoms [10] compared to the general population prevalence of 5% 
[11]. Recent studies have shown that IV iron therapy offers a rapid solution to 
replenishing body iron stores and diminishes or eliminates RLS symptoms in those 
with comorbid iron deficiency anemia [9]. However, many studies have shown that 
the local brain iron levels seem to be more important than the serum levels for the 
development of RLS [12,13]. Low brain iron levels or deficiency has been found in 
patients with haemochromatosis indicating a possible role of local brain iron 
deficiency in the pathophysiology of RLS and PLMS, even in patients with systemic 
iron overload, such as in patients with hemochromatosis [14] or beta thalassemia. 
So far, there are no published reports to support the notion that beta thalassemia 
patients will follow the example of hemochromatosis patients showing evidence of 
RLS. It is not clear whether iron overload-related complications often seen in beta 
thalassemia patients will include the development or absence of RLS. Therefore, the 
primary aim of the current study was to examine the prevalence of RLS in this sample 
of beta thalassemia patients in central Greece where the prevalence of RLS has been 
assessed recently [15]. Taking into account the association and presence of RLS in 
other conditions characterized by iron overload we expected to observe some cases of 
RLS in the examined sample of beta thalassemia patients. Secondary aims were to 
investigate potential associations – if any - of RLS with quality of life levels, sleep 
quality, daily sleepiness, fatigue and depression levels.  
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Materials and methods  
Participants 
From May of 2012 to May of 2013 a total of 114 patients (54 female) were recruited 
from the thalassemia units of Hospitals of Larissa, Trikala and Karditsa, Greece.  
Patients were screened for RLS by an expert Neurologist (GMH) based on the 4 
international RLS study group diagnostic criteria [4] while the severity of RLS 
symptoms was evaluated using the IRLSSG severity scale [16]. 
The inclusion criteria for this study were: Participants with beta thalassemia aged 
between 18-70 years and with clinical stable condition. Exclusion criteria included 
diagnosed neuropathies or reasons for being in a catabolic state within 3 months prior 
to the start of the study.  
All patients gave their written informed consent prior to study participation. The study 
was approved by the Ethics Committee of the University of Thessaly (29/03/2012-
519), Greece and the associated hospitals. 
 
Biochemical assessment 
Hematological and biochemical indices included the levels of Hemoglobin, 
Hematocrit, Glucose, Urea, Creatinine, Serum glutamic oxaloacetic transaminase 
(SGOT), Albumin, Total cholesterol, Triglycerides, High density lipoprotein (HDL), 
Low density lipoprotein (LDL), C reactive protein (CRP), Ferritin, Iron, Potassium 
and Phosphorus. The biochemical analysis was performed at the clinical labs of 
hospitals of Trikala, Larissa and Karditsa under standard hospital procedures. 
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Questionnaires 
All questionnaires were completed with the interview method by experienced 
personnel. We should note that all the questionnaires used in the current study have 
been used before in various RLS studies [17,18].  
Fatigue levels were assessed using the fatigue severity scale (FSS)[19].The patients' 
depression levels were evaluated by using a questionnaire developed by Zung[20].Τhe 
Epworth sleepiness scale (ESS) was used to assess the daily sleepiness level of the 
patients[21]. Patient’s quality of sleep was evaluated using a weekly sleep diary. This 
diary is adapted from the University of Massachusetts Medical School website.  
Finally, the patient's subjective QoL outcomes were evaluated by using a Short Form-
36 Health Survey (SF-36) version modified for patients receiving HD therapy [22]. 
Data are presented in Table 1 & 2 
 
Statistical analysis 
Descriptive statistics and analysis of the data was carried out using the SPSS version 
18 software and the level for statistical significance was set at P<0.05.Normality of 
data was assessed using the  Kolmogorov-Smirnov test. 
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Results  
The patients’ characteristics are presented in Table 1. No patients with RLS or 
conditions mimic RLS were found in the current study. Since no RLS positive 
patients were found, the IRLS severity scale was not evaluated in none of the 
participants. As it was expected due to the nature of their disease, the patients present 
low hematocrit and hemoglobin levels, low HDL and increased ferritin levels. The 
data derived by the various questionnaires are presented in Table 2. 
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Discussion  
To our surprise, no presence of RLS in this sample of patients with beta thalassemia 
was detected. We believe that the adequate levels of iron and ferritin which observed 
in the current study and often seen in these patients could be the reason of the absence 
of RLS symptoms. 
Beta thalassemia is a hereditary blood disorder and is particularly prevalent among 
people living in Mediterranean countries, including Greece. The prevalence of beta 
thalassemia in Greece is 0,04% while RLS is affecting the 3,9% of the Greek general 
population [15], and the 27% of the Greek hemodialysis patients [23]. 
According to the most accepted hypothesis, the pathophysiology of RLS is centered 
on dopaminergic dysfunction in the central nervous system [24]. In addition, there is 
evidence to suggest that defect in the brain iron metabolism may contribute to the 
pathogenesis of the disease [24]. Iron is a cofactor for tyrosine hydroxylase, which is 
a rate-limiting step in the conversion of levodopa to dopamine[25].In animals iron 
deficiency anemia is associated with D2 receptorshypofunction  and should be treated 
with iron therapy. In addition, RLS severity reported to worsen in patients with low 
ferritin levels [24]. It is noteworthy that published data reveal that treatment with 
intravenous iron could successfully ameliorate the RLS symptoms both in primary 
and secondary RLS patients [26]. 
 
Patients with beta thalassemia have increased iron levels in blood serum [27], in 
cerebrospinal fluid[28]and in the brain while regular transfusion therapy could lead to 
iron overload with negative impact to overall health[29,30]. Deposition of iron in the 
brain can contribute to the formation of free radicals, leading to lipid peroxidation and 
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neurotoxicity[31]. Iron deposition in the central nervous system can occur in 
thalassemia, Parkinson disease and other diseases [30]. It was for that reason that we 
believed that RLS could be present in patients with beta thalassemia, however, the 
findings reject our original hypothesis as no RLS case was found in this sample of 
beta thalassemia patients in Greece.  
Various physiological mechanisms could explain at least in part the lack of RLS 
symptoms in this group of patients.  It seems that neurotoxicity which can be present 
in patients with thalassemia does not influence the dopaminergic system of the brain 
which is may be responsible for idiopathic RLS[24].In addition, we do not examined  
the levels of iron in the brain, which is considered to be another possible 
pathophysiological pathway responsible for RLS [24]. The high ferritin value of the 
patients may also lead to the no RLS symptoms presence in our sample. Those levels 
are explained due to increased iron absorption from the gastrointenstinal system and 
also because of the overload of the patients due to frequent transfusions. 
Some limitations in the current study need to be acknowledged. The lack of control 
group seems to be a major pitfall. In the original design will have included as a 
control group all RLS negative patients, however, in the case of negative findings (0% 
RLS prevalence) this is less of importance.  
In conclusion, the data of the present study reveal no RLS cases in this sample of beta 
thalassemia patients. One of the more direct possibilities to be explored is whether the 
iron over loading will result in no RLS prevalence in these patients and also if it could 
lead to the discovery of new treatment approaches. 
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Table 1.Patients characteristics and biochemical data 
Variable Mean ± SD 
Ν 114 
Men/Women 59/55 
Age (Years) 39.6±11.4 
Weight (Kg) 64.4±11.8 
Height (m) 1.67±0.08 
Body Mass Index 22.9±3.4 
Hemoglobin  ( g/dl) 9.8±1.1 
Haematocrit (HCT) (%) 29.9±3.03 
Glucose (mg/dl) 95.4±23.4 
Urea (mg/dl) 35.3±10.5 
Creatinine (mg/dl) 0.7±0.2 
Serum glutamic oxaloacetic transaminase (SGOT) 
(IU/l) 
34.1±20.7 
Albumin (g/dl) 4.5±0.4 
Total cholesterol ( mg/dl) 125.5±31.7 
Triglycerides (mg/dl) 124±68.1 
High density lipoprotein (HDL) (mg/dl) 34.7±11.2 
Low density lipoprotein (LDL) ( mg/dl) 63.5±26.3 
C reactive protein (CRP) (mg/dl) 0.5±0.3 
Ferritin (ng/dl) 1836.7±2251 
Iron (mg/dl) 202.5±61 
Potassium (mmol/l) 4.5±0.4 
Phosphorus (mg/dl) 3.9±0.7 
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Table  2. Quality of life, depression score, sleep quality and fatigue data in patients 
with beta thalassemia. 
Variables Mean ± SD 
Zung Depression Scale 35.5±8.3 
Sleep Quality 6.5±2.9 
Epworth Sleepiness Scale 6.6±3.5 
Fatigue Severity Scale 3.1±1.6 
SF-36 questionnaire data 
Physical function scale 87.8±20.9 
Role-physical scale 84.8±32.8 
Body pain scale 80.1±27.8 
General health scale 60.9±24.7 
Vitality scale 75.5±18.9 
Social functioning scale 88.0±24.8 
Role emotional scale 85.5±32.0 
Mental health scale 72.8±18.8 
Physical health Component summary 77.8±18.7 
Mental health Component summary 76.5±17.5 
Total SF 36 Score 79.4±18.0 
 
 
